Skip to main content
Defiance International

Published study records

Study records for VIP

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

4,874 study records.

71 evidence-verified · 3,324 citation-verified · 1,479 identifier-confirmed · 0 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 1,407
  • In vivo/preclinical: 1,745
  • Review/meta-analysis: 186
  • Other: 0
Filter study recordsReset filters

Current study records

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2026

Calretinin and Parvalbumin Trapping of TDP43 and XRCC1 Instructs Neocortical Interneuron Death in Neonatal Hypoxic-Ischemic Encephalopathy.

Biomolecules · 2026

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Slightly older piglets (7–10 days old, 3.0–4.5 kg, males and females) were subjected to HI (n = 21) and sham (n = 6) procedures for neuropathology outcomes and scalp EEG recordings with survival of 4 days.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2025

Biologically grounded neocortex computational primitives implemented on neuromorphic hardware improve vision transformer performance.

Proceedings of the National Academy of Sciences of the United States of America · 2025

Study scale: It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Not reported in the declared source.

Study scale

It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.

Intervention or exposure

Not reported in the declared source.

Comparator

Not reported in the declared source.

Outcomes examined

By parametrically varying synaptic conductances within physiologically realistic bounds, we quantified the distinct computational roles of each inhibitory subtype in shaping pyramidal output and circuit-level dynamics (Fig. 2 D and E).

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2025

Adenine base editing of CFTR using receptor targeted nanoparticles restores function to G542X cystic fibrosis airway epithelial cells.

Cellular and molecular life sciences : CMLS · 2025

Study scale: (n = 3) using OdysseyCLx fluorescence data.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In this study, we explored the hypothesis that delivery of ABE using novel self-assembling receptor targeted lipid nanoparticles (RTN) and conversion of G542X to G542R could lead to a therapeutically functional treatment.

Study design

Not reported in the declared source.

Participants or experimental system

We used an adenine base editor (ABE8e Cas9) and guide RNA (sgRNA)/enhanced green fluorescent protein (EGFP) plasmids encapsulated in receptor targeted nanoparticles (RTN), delivered to Bmi-1 transduced basal human CF airway epithelial cells harbouring the homozygous CFTR G542X variant, to convert the stop codon to G542R, a variant which is amenable to modulator therapy.

Study scale

(n = 3) using OdysseyCLx fluorescence data.

Intervention or exposure

Treatment with ETI was performed 24 h prior to functional assessment with 1 μM VX-445, 3 μM VX-661, and 1 μM VX-770.

Comparator

Treatment with IL-1β was used as a positive control.

Outcomes examined

We assessed editing efficiency of ABE delivered as plasmid DNA also encoding EGFP, by RTN to CFTR G542X homozygous airway epithelial cells.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

Mitofusin 2 controls mitochondrial and synaptic dynamics of suprachiasmatic VIP neurons and related circadian rhythms.

The Journal of clinical investigation · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Given the indispensable role of SCN VIP neurons in maintaining circadian rhythm (5), we examined here the effect of mitofusin 2 (Mfn2), a mitochondrial membrane protein involved in the control of the fusion process (19), on SCN VIP neuronal activity and downstream effects on behavior, thermoregulation, and sleep.

Study design

To visualize VIP neurons, Cre-dependent tdTomato reporter control Ai14 mice (Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J; strain JAX:007914) crossed with Mfn2–/– mice were used for histological analysis and ex vivo electrophysiological recordings at the age of 1.5–3 months.

Participants or experimental system

To determine the effect of the SCN circadian oscillation in the LD cycle at the cellular level, we first analyzed synapse density and mitochondrial morphology in SCN core VIP- expressing neurons of C57BL/6J mice at Zeitgeber times (ZT) 1, 7, 13, 19, (ZT0: lights on; ZT12: lights off).

Study scale

Not reported in the declared source.

Intervention or exposure

Not reported in the declared source.

Comparator

Compared with the control animals, they had shifted activity onset toward the light phase, resulting in higher activity counts during the light phase and statistically lower activity counts during the dark phase, but without changes in their total activity level (Figure 4, D and E).

Outcomes examined

Along with mitochondria modifications in SCN VIP neurons of Mfn2–/– mice, we analyzed daily rearrangements of the number of synapses in these neurons.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2025

GluN2C/D-containing NMDA receptors enhance temporal summation and increase sound-evoked and spontaneous firing in the inferior colliculus.

The Journal of physiology · 2025

Study scale: Male (n = 18) and female (n = 15) mice aged P30–P66 were used.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Here, we tested whether GluN2C/D‐containing NMDARs mediate NMDAR currents in the IC, as well as the role of these receptors in synaptic integration and sound processing.

Study design

The signal was developed using the horseradish peroxidase for each channel and then opal dyes diluted at 1:1000 were assigned for each channel: tdTomato was assigned to Opal 690 (catalog. no. FP1497001KT; Akoya Bioscience, Marlborough, MA, USA), Glun2c was assigned to Opal 570 (catalog. no. FP1488001KT; Akoya Bioscience), and Glun2d was assigned to Opal 520 (catalog. no. FP1487001KT; Akoya Bioscience).

Participants or experimental system

Animals were kept under a 12:12 h light/dark photocycle with food and water available ad libitum.

Study scale

Male (n = 18) and female (n = 15) mice aged P30–P66 were used.

Intervention or exposure

Recording pipettes were pulled from borosilicate glass capillaries (outer diameter 1.5 mm, inner diameter 0.86 mm; Sutter Instrument) with a P‐1000 microelectrode puller (Sutter Instrument) and filled with an internal solution containing (in mm): 115 CsOH, 115 d‐gluconic acid, 7.76 CsCl, 0.5 EGTA, 10 HEPES, 10 Na2 phosphocreatine, 4 MgATP and 0.3 NaGTP, supplemented with 0.1% biocytin (w/v), pH adjusted to 7.4 with CsOH and osmolality to 290 mosmol kg–1 with sucrose.

Comparator

To test for vehicle effects, we performed control experiments where puff‐elicited EPSCs were compared between control and DMSO (vehicle) conditions.

Outcomes examined

Co‐localization of Glun2c and Glun2d in tdTomato‐positive neurons was quantified manually using Neurolucida 360 (MBF Bioscience, Williston, VT, USA).

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

Reward history guides focal attention in whisker somatosensory cortex.

Nature communications · 2025

Study scale: This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Here, we developed an experimental model of focal attention based on reward history in the mouse whisker tactile system and used it to investigate the neurobiological basis of attention in the sensory cortex.

Study design

Not reported in the declared source.

Participants or experimental system

We studied attentional behavior in head-fixed mice during a Go/NoGo whisker touch detection task, which included Go stimuli on many different whiskers.

Study scale

This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).

Intervention or exposure

To motivate behavioral training, each mouse received 0.8–1.5 mL of water daily, calibrated to maintain 85% of pre-training body weight.

Comparator

When the prior trial was a NoGo, mice detected the current Go whisker with d’ = 1.13 ± 0.02 (termed d’NoGo, mean ± SEM across 476 sessions, 22 mice), which we consider baseline detection sensitivity. d’ for detecting a given Go whisker was elevated following 1 prior Hit to the same whisker, and even more so following multiple consecutive Hits to the same whisker (d’>1HitSame = 2.45 ± 0.11, p = 1.0e-4 vs d’NoGo, permutation test).

Outcomes examined

Expert mice effectively distinguished Go from NoGo trials, quantified by d’ from signal detection theory (Supplementary Fig. S1A).

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

Parvalbumin Interneuron-Dependent Hippocampal Neurogenesis Evoked by Prolonged Rhythmic Light Flicker.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Spatial learning performance was evaluated using the active place avoidance (APA) test from day 25 to day 30 (Figure 1A).

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2024

The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility recovery and inflammation improvement in early-stage acute pancreatitis patients.

BMC gastroenterology · 2024

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

After admission, the enrolled patients were divided into two groups by SPSS computer randomization method: one group was TGP group, and the other group was conventional treatment group.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Sixty-five AP patients were randomly divided into conventional treatment group and TGP group.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2024

Sensory neurons regulate stimulus-dependent humoral immunity in mouse models of bacterial infection and asthma.

Nature communications · 2024

Study scale: Naïve n = 6, Naïve RTX: n = 5; Day 1: Veh: n = 4, RTX: n = 4; Day 8: Veh: n = 5, RTX: n = 5; Day 10: Veh: n = 13, RTX: n = 5; Day 11: Veh: n = 13, RTX: n = 5; Day 15: Veh: n = 5, RTX: n = 5.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Next, we determined whether nociceptors regulated pro-inflammatory-cytokine production before lung infection clearance.

Study design

All in vivo cells were gated on leukocytes, singlets, live, CD45+.

Participants or experimental system

To confirm the B cell-neutrophil axis, naïve neutrophils were incubated with decomplemented serum harvested from sensory neuron intact and RTX ablated mice, which underwent our pre-exposure and infection model, as well as naïve mice.

Study scale

Naïve n = 6, Naïve RTX: n = 5; Day 1: Veh: n = 4, RTX: n = 4; Day 8: Veh: n = 5, RTX: n = 5; Day 10: Veh: n = 13, RTX: n = 5; Day 11: Veh: n = 13, RTX: n = 5; Day 15: Veh: n = 5, RTX: n = 5.

Intervention or exposure

Data from 2 independent experiments. f–i B cells were isolated from spleens of naïve mice and cultured in media with IL4 + LPS and supplemented with VIP or NPY.

Comparator

Mice received escalating doses of resiniferatoxin (RTX) or Vehicle (Veh) starting 21 days prior to inoculation.

Outcomes examined

Given the high expression of VIPR1 on B cells, we tested the effects of VIP stimulation in WT and VIPR1–/– isolated B cells.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2024

Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD.

Hepatology communications · 2024

Study scale: Average based on n = 6 in each group.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Given the described hepatoprotective role of IL-22, we hypothesize that modulation of this neuroimmune circuit could potentially be an innovative approach for the control of liver steatosis.

Study design

Not reported in the declared source.

Participants or experimental system

We used a model of diet-induced MASLD by exposing mice to a high-fat diet (HFD) for 16 weeks, when the development of liver steatosis was first observed in our animals.

Study scale

Average based on n = 6 in each group.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not reported in the declared source.

Outcomes examined

We characterized IL-22 production by intestinal ILC3 at this dietary endpoint.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Bordetella spp. utilize the type 3 secretion system to manipulate the VIP/VPAC2 signaling and promote colonization and persistence of the three classical Bordetella in the lower respiratory tract.

Frontiers in cellular and infection microbiology · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not reported in the declared source.

Outcomes examined

To evaluate the antimicrobial activity of VIP (Sigma Aldrich, cat number V6130-250UG) the experiments were performed in a 96-well plate (Corning, Coastar, Cat number 3591).

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2023

Ferroptosis in the Lacrimal Gland Is Involved in Dry Eye Syndrome Induced by Corneal Nerve Severing.

Investigative ophthalmology & visual science · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked